Hypocalcemia pathophysiology: Difference between revisions

Jump to navigation Jump to search
Line 56: Line 56:
* Mutations in the transcription factor glial-cell missing B (GCMB).  
* Mutations in the transcription factor glial-cell missing B (GCMB).  
* Mutations in the calcium-sensing receptor, results in Autosomal dominant hypocalcemia (ADH).which is of 2 types<ref name="pmid8733126">{{cite journal |vauthors=Baron J, Winer KK, Yanovski JA, Cunningham AW, Laue L, Zimmerman D, Cutler GB |title=Mutations in the Ca(2+)-sensing receptor gene cause autosomal dominant and sporadic hypoparathyroidism |journal=Hum. Mol. Genet. |volume=5 |issue=5 |pages=601–6 |date=May 1996 |pmid=8733126 |doi= |url=}}</ref><ref name="pmid11152759">{{cite journal |vauthors=Brown EM, MacLeod RJ |title=Extracellular calcium sensing and extracellular calcium signaling |journal=Physiol. Rev. |volume=81 |issue=1 |pages=239–297 |date=January 2001 |pmid=11152759 |doi=10.1152/physrev.2001.81.1.239 |url=}}</ref>
* Mutations in the calcium-sensing receptor, results in Autosomal dominant hypocalcemia (ADH).which is of 2 types<ref name="pmid8733126">{{cite journal |vauthors=Baron J, Winer KK, Yanovski JA, Cunningham AW, Laue L, Zimmerman D, Cutler GB |title=Mutations in the Ca(2+)-sensing receptor gene cause autosomal dominant and sporadic hypoparathyroidism |journal=Hum. Mol. Genet. |volume=5 |issue=5 |pages=601–6 |date=May 1996 |pmid=8733126 |doi= |url=}}</ref><ref name="pmid11152759">{{cite journal |vauthors=Brown EM, MacLeod RJ |title=Extracellular calcium sensing and extracellular calcium signaling |journal=Physiol. Rev. |volume=81 |issue=1 |pages=239–297 |date=January 2001 |pmid=11152759 |doi=10.1152/physrev.2001.81.1.239 |url=}}</ref>
** Type 1:  Autosomal dominant hypocalcemia (ADH) 1 is due to activating mutation in the CaSR.<ref name="pmid9253358">{{cite journal |vauthors=De Luca F, Ray K, Mancilla EE, Fan GF, Winer KK, Gore P, Spiegel AM, Baron J |title=Sporadic hypoparathyroidism caused by de Novo gain-of-function mutations of the Ca(2+)-sensing receptor |journal=J. Clin. Endocrinol. Metab. |volume=82 |issue=8 |pages=2710–5 |date=August 1997 |pmid=9253358 |doi=10.1210/jcem.82.8.4166 |url=}}</ref>  
** Type 1:  Autosomal dominant hypocalcemia (ADH) 1 is due to activating mutation in the CaSR.<ref name="pmid9253358">{{cite journal |vauthors=De Luca F, Ray K, Mancilla EE, Fan GF, Winer KK, Gore P, Spiegel AM, Baron J |title=Sporadic hypoparathyroidism caused by de Novo gain-of-function mutations of the Ca(2+)-sensing receptor |journal=J. Clin. Endocrinol. Metab. |volume=82 |issue=8 |pages=2710–5 |date=August 1997 |pmid=9253358 |doi=10.1210/jcem.82.8.4166 |url=}}</ref><ref name="pmid12915654">{{cite journal |vauthors=Hendy GN, Minutti C, Canaff L, Pidasheva S, Yang B, Nouhi Z, Zimmerman D, Wei C, Cole DE |title=Recurrent familial hypocalcemia due to germline mosaicism for an activating mutation of the calcium-sensing receptor gene |journal=J. Clin. Endocrinol. Metab. |volume=88 |issue=8 |pages=3674–81 |date=August 2003 |pmid=12915654 |doi=10.1210/jc.2003-030409 |url=}}</ref>  
** Type 2: Autosomal dominant hypocalcemia (ADH) 2 is due to activating mutation in the guanine nucleotide binding protein, alpha 11 gene(''GNA11)''.<ref name="pmid24823460">{{cite journal |vauthors=Li D, Opas EE, Tuluc F, Metzger DL, Hou C, Hakonarson H, Levine MA |title=Autosomal dominant hypoparathyroidism caused by germline mutation in GNA11: phenotypic and molecular characterization |journal=J. Clin. Endocrinol. Metab. |volume=99 |issue=9 |pages=E1774–83 |date=September 2014 |pmid=24823460 |pmc=4154081 |doi=10.1210/jc.2014-1029 |url=}}</ref><ref name="pmid23802516">{{cite journal |vauthors=Nesbit MA, Hannan FM, Howles SA, Babinsky VN, Head RA, Cranston T, Rust N, Hobbs MR, Heath H, Thakker RV |title=Mutations affecting G-protein subunit α11 in hypercalcemia and hypocalcemia |journal=N. Engl. J. Med. |volume=368 |issue=26 |pages=2476–2486 |date=June 2013 |pmid=23802516 |pmc=3773604 |doi=10.1056/NEJMoa1300253 |url=}}</ref>  
** Type 2: Autosomal dominant hypocalcemia (ADH) 2 is due to activating mutation in the guanine nucleotide binding protein, alpha 11 gene(''GNA11)''.<ref name="pmid24823460">{{cite journal |vauthors=Li D, Opas EE, Tuluc F, Metzger DL, Hou C, Hakonarson H, Levine MA |title=Autosomal dominant hypoparathyroidism caused by germline mutation in GNA11: phenotypic and molecular characterization |journal=J. Clin. Endocrinol. Metab. |volume=99 |issue=9 |pages=E1774–83 |date=September 2014 |pmid=24823460 |pmc=4154081 |doi=10.1210/jc.2014-1029 |url=}}</ref><ref name="pmid23802516">{{cite journal |vauthors=Nesbit MA, Hannan FM, Howles SA, Babinsky VN, Head RA, Cranston T, Rust N, Hobbs MR, Heath H, Thakker RV |title=Mutations affecting G-protein subunit α11 in hypercalcemia and hypocalcemia |journal=N. Engl. J. Med. |volume=368 |issue=26 |pages=2476–2486 |date=June 2013 |pmid=23802516 |pmc=3773604 |doi=10.1056/NEJMoa1300253 |url=}}</ref>  



Revision as of 17:54, 21 June 2018

https://https://www.youtube.com/watch?v=KWZrSYo7xuk%7C350}}

Hypocalcemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hypocalcemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hypocalcemia pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hypocalcemia pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hypocalcemia pathophysiology

CDC on Hypocalcemia pathophysiology

Hypocalcemia pathophysiology in the news

Blogs on Hypocalcemia pathophysiology

Directions to Hospitals Treating Hypocalcemia

Risk calculators and risk factors for Hypocalcemia pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vamsikrishna Gunnam M.B.B.S [2]

Overview

Hypocalcemia may develop in disorders associated with insufficient parathyroid hormone or vitamin D production or resistance to hormonal activities. Perturbations of calcium homeostasis can be caused by environmental factors or occur as a result of genetic mutations in the calcium-sensing receptor (as in type 1 autosomal dominant hypocalcemia), Gs α subunit (as in type 1A and 1B pseudohypoparathyroidism), vitamin D hydroxylase (as in type 1 vitamin D-dependent rickets , and calcitriol receptor (as in type 2 vitamin D-dependent rickets).

Pathophysiology

Physiology

The normal physiology of Hypocalcemia can be understood as follows:[1][2]

  • The normal concentrations of calcium in the body is maintained within the narrow range and that is required for the minimal activity of the many extra- and intracellular processes calcium regulates. 
  • Calcium transport within the blood is mainly bound to plasma proteins like albumin (45%), phosphate and citrate(15%) and ionized state(40%).
  • Only the ionized form of calcium is active but most laboratories show report of total serum calcium concentrations.
  • The normal concentration of calcium ranges between 8.5 and 10.5 mg/dL.
  • The normal range of ionized calcium in the plasma is 4.65 to 5.25 mg/dL.

Pathogenesis

It is understood that Hypocalcemia is the result caused by the following

Hypoalbuminemia

  • When there is a fluctuation in the protein concentrations especially the one protein which is albumin,total calcium levels in the blood may change.[3][4]
  • Whereas the levels of ionized calcium(free form) remains mostly constant, because it is hormonally regulated.
  • So that the total serum calcium levels may not accurately reflect the physiologically important ionized calcium concentration.

Hormone regulation 

  • Parathyroid hormone (PTH) and vitamin D play a important role in regulating serum calcium.[5]
  • Calcium by itself controls to regulate its own serum levels via a calcium-sensing receptor (CaSR) in the parathyroid gland to inhibit parathyroid hormone (PTH) secretion and on a CaSR in the loop of Henle of the kidney to stimulate renal calcium excretion.[6][7][8][9]
  • Whenever the body serum ionized calcium goes down even in small amounts PTH (parathyroid hormone) is secreted instantaneously.And this occurs in 3 ways[10][11][12][13]
    • 1)PTH (parathyroid hormone) stimulation of calcium reabsorption in the distal tubule of the kidney results in decreased urinary calcium excretion by the kidney.[14]
    • 2)PTH (parathyroid hormone) increases renal production of 1,25-dihydroxyvitamin D which is also called as calcitriol which in turn increases the intestinal calcium absorption.[15]
    • 3)PTH (parathyroid hormone) increases bone resorption which in turn increases the serum calcium levels.[16]
  • When PTH secretion is insufficient Hypokalemia may occur as the sequel, which is classically seen in hypoparathyroidism.

Acid-base disturbances

Alkalosis

  • In alkalosis, hydrogen ions dissociate from the negatively charged albumin, which allows for increased calcium binding and leads to a decreased concentration of free calcium.
  • For an increase in pH of 0.1 unit, there is an approximately 0.05 mmol/L (0.1 mEq/L) fall in the serum level of ionized calcium.

Respiratory Alkalosis

Globulin Binding

Calcium binding to globulin is relatively small (1.0 g of globulin binds 0.2–0.3 mg of calcium) and generally does not influence the total serum calcium concentration.[17]

Genetics

The development of hypocalcemia is the result of genetic mutations such as

  • Mutations in the transcription factor glial-cell missing B (GCMB).
  • Mutations in the calcium-sensing receptor, results in Autosomal dominant hypocalcemia (ADH).which is of 2 types[18][19]
    • Type 1: Autosomal dominant hypocalcemia (ADH) 1 is due to activating mutation in the CaSR.[20][21]
    • Type 2: Autosomal dominant hypocalcemia (ADH) 2 is due to activating mutation in the guanine nucleotide binding protein, alpha 11 gene(GNA11).[22][23]

References

  1. Fong J, Khan A (February 2012). "Hypocalcemia: updates in diagnosis and management for primary care". Can Fam Physician. 58 (2): 158–62. PMC 3279267. PMID 22439169.
  2. Carroll R, Matfin G (February 2010). "Endocrine and metabolic emergencies: hypocalcaemia". Ther Adv Endocrinol Metab. 1 (1): 29–33. doi:10.1177/2042018810366494. PMC 3474611. PMID 23148147.
  3. Fong J, Khan A (February 2012). "Hypocalcemia: updates in diagnosis and management for primary care". Can Fam Physician. 58 (2): 158–62. PMC 3279267. PMID 22439169.
  4. Carroll R, Matfin G (February 2010). "Endocrine and metabolic emergencies: hypocalcaemia". Ther Adv Endocrinol Metab. 1 (1): 29–33. doi:10.1177/2042018810366494. PMC 3474611. PMID 23148147.
  5. Riccardi D, Brown EM (March 2010). "Physiology and pathophysiology of the calcium-sensing receptor in the kidney". Am. J. Physiol. Renal Physiol. 298 (3): F485–99. doi:10.1152/ajprenal.00608.2009. PMC 2838589. PMID 19923405.
  6. Goodman WG (January 2004). "Calcium-sensing receptors". Semin. Nephrol. 24 (1): 17–24. PMID 14730506.
  7. Quarles LD (July 2003). "Extracellular calcium-sensing receptors in the parathyroid gland, kidney, and other tissues". Curr. Opin. Nephrol. Hypertens. 12 (4): 349–55. doi:10.1097/01.mnh.0000079682.89474.80. PMID 12815330.
  8. Toka HR, Pollak MR (September 2014). "The role of the calcium-sensing receptor in disorders of abnormal calcium handling and cardiovascular disease". Curr. Opin. Nephrol. Hypertens. 23 (5): 494–501. doi:10.1097/MNH.0000000000000042. PMID 24992569.
  9. Egbuna OI, Brown EM (March 2008). "Hypercalcaemic and hypocalcaemic conditions due to calcium-sensing receptor mutations". Best Pract Res Clin Rheumatol. 22 (1): 129–48. doi:10.1016/j.berh.2007.11.006. PMC 2364635. PMID 18328986.
  10. Blaine J, Chonchol M, Levi M (July 2015). "Renal control of calcium, phosphate, and magnesium homeostasis". Clin J Am Soc Nephrol. 10 (7): 1257–72. doi:10.2215/CJN.09750913. PMC 4491294. PMID 25287933.
  11. Akerström G, Hellman P, Hessman O, Segersten U, Westin G (April 2005). "Parathyroid glands in calcium regulation and human disease". Ann. N. Y. Acad. Sci. 1040: 53–8. doi:10.1196/annals.1327.005. PMID 15891005.
  12. Carroll R, Matfin G (February 2010). "Endocrine and metabolic emergencies: hypocalcaemia". Ther Adv Endocrinol Metab. 1 (1): 29–33. doi:10.1177/2042018810366494. PMC 3474611. PMID 23148147.
  13. Carrillo-López N, Fernández-Martín JL, Cannata-Andía JB (2009). "[The role of calcium, calcitriol and their receptors in parathyroid regulation]". Nefrologia (in Spanish; Castilian). 29 (2): 103–8. doi:10.3265/Nefrologia.2009.29.2.5154.en.full. PMID 19396314.
  14. Wu X, Sonnenberg H (November 1995). "Effect of renal perfusion pressure on excretion of calcium, magnesium, and phosphate in the rat". Clin. Exp. Hypertens. 17 (8): 1269–85. PMID 8563701.
  15. Mortensen L, Hyldstrup L, Charles P (January 1997). "Effect of vitamin D treatment in hypoparathyroid patients: a study on calcium, phosphate and magnesium homeostasis". Eur. J. Endocrinol. 136 (1): 52–60. PMID 9037127.
  16. Poole, K; Reeve, J (2005). "Parathyroid hormone — a bone anabolic and catabolic agent". Current Opinion in Pharmacology. 5 (6): 612–617. doi:10.1016/j.coph.2005.07.004. ISSN 1471-4892.
  17. Taal, Maarten (2012). Brenner & Rector's the kidney. Philadelphia, PA: Elsevier/Saunders. ISBN 978-1416061939.
  18. Baron J, Winer KK, Yanovski JA, Cunningham AW, Laue L, Zimmerman D, Cutler GB (May 1996). "Mutations in the Ca(2+)-sensing receptor gene cause autosomal dominant and sporadic hypoparathyroidism". Hum. Mol. Genet. 5 (5): 601–6. PMID 8733126.
  19. Brown EM, MacLeod RJ (January 2001). "Extracellular calcium sensing and extracellular calcium signaling". Physiol. Rev. 81 (1): 239–297. doi:10.1152/physrev.2001.81.1.239. PMID 11152759.
  20. De Luca F, Ray K, Mancilla EE, Fan GF, Winer KK, Gore P, Spiegel AM, Baron J (August 1997). "Sporadic hypoparathyroidism caused by de Novo gain-of-function mutations of the Ca(2+)-sensing receptor". J. Clin. Endocrinol. Metab. 82 (8): 2710–5. doi:10.1210/jcem.82.8.4166. PMID 9253358.
  21. Hendy GN, Minutti C, Canaff L, Pidasheva S, Yang B, Nouhi Z, Zimmerman D, Wei C, Cole DE (August 2003). "Recurrent familial hypocalcemia due to germline mosaicism for an activating mutation of the calcium-sensing receptor gene". J. Clin. Endocrinol. Metab. 88 (8): 3674–81. doi:10.1210/jc.2003-030409. PMID 12915654.
  22. Li D, Opas EE, Tuluc F, Metzger DL, Hou C, Hakonarson H, Levine MA (September 2014). "Autosomal dominant hypoparathyroidism caused by germline mutation in GNA11: phenotypic and molecular characterization". J. Clin. Endocrinol. Metab. 99 (9): E1774–83. doi:10.1210/jc.2014-1029. PMC 4154081. PMID 24823460.
  23. Nesbit MA, Hannan FM, Howles SA, Babinsky VN, Head RA, Cranston T, Rust N, Hobbs MR, Heath H, Thakker RV (June 2013). "Mutations affecting G-protein subunit α11 in hypercalcemia and hypocalcemia". N. Engl. J. Med. 368 (26): 2476–2486. doi:10.1056/NEJMoa1300253. PMC 3773604. PMID 23802516.

Template:WS Template:WH